Magnera

Magnera reported Q2 EPS of -$0.50, missing the expected $0.2032; revenue was $796 million versus a forecast of $803.42 million. Despite the results, the stock rose 16.11% in after-hours trading, supported by strong free cash flow of $73 million in the quarter and strategic initiatives. Management affirmed the full-year outlook with an EBITDA target corridor of $380–410 million and expects to make up weather-related setbacks in the second half of the year. » More on de.investing.com

Magnera reports Q2 2026 revenue of $796 million and EPS of -$0.50, missing consensus expectations by a wide margin. Winter storms in North America, the contractual pass-through of lower raw material costs and weaker demand in Europe reduced volumes, while adjusted EBITDA remained largely stable at $90 million. Free cash flow was $73 million, underscoring operational resilience; management confirms the full-year guidance (adjusted EBITDA $380–410 million, free cash flow $90–110 million). Magnera highlights cost-reduction measures, regional sourcing and merger synergies as drivers of margin stability. » More on de.investing.com

Magnera reported Q4 revenue of $839 million, exceeding the consensus of $834.06 million, after which the stock climbed 40.7% premarket to $11.20. Drivers were strong results in consumer solutions and infection-protection products; adjusted EBITDA was $90 million and free cash flow $126 million. The company reduced leverage to 3.8x and reports significant cost savings. For 2026 Magnera expects EBITDA growth of around 9%, free cash flow of $90–110 million and plans $80 million in investments with stagnant volumes. » More on de.investing.com